Tumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies
|
|
- Leon Burke
- 6 years ago
- Views:
Transcription
1 DOCTYPE = ARTICLE Tumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies Eleanor Hendershot, MN, RN, ACNP Alberto Pappo, MD David Malkin, MD Lillian Sung, MD Tumor necrosis following preoperative chemotherapy in patients with osteosarcoma is a predictor of overall survival. With modern therapies, 45% of patients are expected to achieve more than 90% tumor necrosis. Investigators at the authors center, however, increasingly noted that patients were experiencing inferior necrosis responses. A retrospective study of treated patients at the center was undertaken to examine this. The purpose of this study was to determine (1) whether the number of patients with favorable histological responses had changed over time and (2) whether the percentage of patients with favorable responses was similar to published outcomes. Chart reviews were performed on patients treated from 1993 to 2003 according to the Pediatric Oncology Group 9351, regimen A protocol. Twenty-one patients met all eligibility requirements; 52% of patients had more than 90% necrosis. No correlation existed between degree of necrosis and year of treatment (r = 0.06; P =.8). Patients with osteosarcoma treated at the authors institution have comparable tumor necrosis responses to published outcomes, and no change occurred over time. This study stresses the importance of rigorous retrospective reviews before implementing treatment changes. Key words: osteosarcoma, tumor necrosis, prognostic factors, chemotherapy, survival 2006 by Association of Pediatric Oncology Nurses DOI: / Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. It arises from mesenchymal bone-forming cells and most commonly affects the metaphyseal growth plate of long bones. It affects 5.6 per million children younger than 15 years annually, with a peak incidence occurring in the second decade of life (Hartford et al., 2006). Osteosarcoma occurs more often in African Americans compared with whites and in males compared with females (Link, Gebhardt, & Meyers, 2002). The cause of osteosarcoma is unknown; however, several risk factors have been identified including ionizing radiation and periods of rapid bone growth. Prior diagnosis of retinoblastoma, bone dysplasias, Li-Fraumeni syndrome, Paget s disease, Eleanor Hendershot, MN, RN, ACNP, works in the outpatient hematology/ oncology clinic at the Hospital for Sick Children in Toronto, Ontario, Canada, as the nurse practitioner in the Solid Tumor Program. She is a lecturer in the Faculty of Nursing at the University of Toronto. Alberto Pappo, MD, is a staff oncologist in the Division of Hematology/Oncology at the Hospital for Sick Children. He is the head of the Solid Tumor Section and a professor of pediatrics at the University of Toronto. David Malkin, MD, is a staff oncologist and clinician-scientist in the Division of Hematology/ Oncology at the Hospital for Sick Children. He is a professor of pediatrics and medical biophysics, University of Toronto. Lillian Sung, MD, PhD, is a clinician-scientist in the Division of Hematology/Oncology at the Hospital for Sick Children in Toronto, Ontario. She is an assistant professor in the Department of Pediatrics and the Department of Health Policy Management and Evaluation at the University of Toronto. Address for correspondence: Eleanor Hendershot, MN, RN, ACNP, Division of Hematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8; eleanor.hendershot@ sickkids.ca. 176 Journal of Pediatric Oncology Nursing, Vol 23, No 4 (July-August), 2006: pp
2 Tumor Necrosis in Pediatric Osteosarcoma and Rothmund-Thompson syndrome have also been associated with an increased risk for developing osteosarcoma (Link et al., 2002). Osteosarcoma most commonly occurs in the distal femur, proximal tibia, and proximal humerus and most often metastasizes to lung and bone. Gross metastatic disease is evident at diagnosis in less than 20% of patients (Kager et al., 2003). However, micrometastatic disease is likely almost always present at the time of diagnosis. Patients with osteosarcoma often present with signs and symptoms that may have been present for weeks to months. The most common presenting symptom is a visible or palpable mass in the affected area. Pain is usually a presenting complaint that is often aggravated by physical activity. A history of trauma is not uncommon, although its clinical relevance is unclear. Constitutional symptoms such as fever, weight loss, or night sweats are rare. Radiographs of the affected area will confirm the presence of a destructive bony lesion that can be lytic, sclerotic, or mixed. The presence of a Codman s triangle is characteristic on plain films and represents a periosteal reaction (Ragland, Bell, Lopez, & Siegal, 2002). A sunburst pattern is also occasionally seen on plain radiographs and represents ossification in the soft tissues (Marina, Gebhardt, Teot, & Gorlick, 2004) (Figure 1). Once a tumor is identified, magnetic resonance imaging of the entire affected bone and adjacent soft tissues area should be performed to evaluate the extent of tumor, vascular supply, its proximity to joints and the neurovascular bundle, and skip lesions representing proximal or distal regional metastatic bony disease (Figure 2). The metastatic workup involves imaging of the chest with computed tomography scan to identify any pulmonary nodules. A whole-body bone scan is performed to determine if there are bone metastases. There are no specific blood tests diagnostic of osteosarcoma; however, lactic acid dehydrogenase and alkaline phosphatase levels are elevated in 30% and 50% of patients, respectively (Link et al., 2002). These enzymes reflect osteoclast and osteoblast activity within the bone and may suggest a high tumor burden. A biopsy is performed to confirm the diagnosis of osteosarcoma. Osteosarcoma cells are spindle shaped and are characterized by the production of malignant osteoid (Jurgens, Winkler, & Gobel, 1997). There are various histological subtypes of osteosarcoma, the most common of which is osteoblastic, which is seen in 78% of patients (Pinkerton, 1999). Other histologies Figure 1. Figure 2. Plain Radiograph: Osteosarcoma of Tibia With Visible Sunburst Periosteal Reaction Magnetic Resonance Imaging Showing Osteosarcoma of the Proximal Tibia include chondroblastic and fibroblastic and then, with decreasing frequency, malignant fibrous histiocytomalike, giant cell-rich, telangiectatic, low-grade intraosseous, small cell, and juxtacortical. Tumor staging evaluated using the Enneking staging system is based on the presence of intracompartmental and extracompartmental extension of the tumor as well as tumor grade and the presence of metastases. Journal of Pediatric Oncology Nursing 23(4);
3 Hendershot et al. Tumors are divided into low and high grade depending on the aggressive nature of the tumor and its potential to metastasize (Davis, Bell, & Goodwin, 1994). Osteosarcoma is treated with combined modality therapy that includes surgery and chemotherapy. Both are vital for long-term survival. Osteosarcoma originally treated with surgery alone yielded survival rates of only 15% to 20%, providing compelling evidence that even in the absence of overt metastases at diagnosis, micrometastases are likely present and cause disease recurrence (Marina et al., 2004). Local control must always be in the form of surgical resection because osteosarcoma is not generally a radiosensitive tumor. The use of adjuvant chemotherapy over the past 20 years has dramatically improved the outcome of these patients. The concept of preoperative chemotherapy was pioneered at Memorial-Sloan Kettering Cancer Center (Rosen et al., 1979). The goals of preoperative chemotherapy are 3-fold: the immediate treatment of micrometastatic disease, limb preservation, and assessment of response to chemotherapy. The most commonly used chemotherapeutic agents include doxorubicin, cisplatin, and high-dose methotrexate (Zalupski et al., 2004). Some investigators have also advocated the use of etoposide and ifosfamide, especially in the presence of metastatic disease. Several cycles of chemotherapy are given, followed by surgical resection of the tumor. This is then followed by maintenance chemotherapy using the same agents. The 3-year disease-free survival in localized osteosarcoma is in the range of 60% to 70% (Bacci et al., 2002). Those who respond well to preoperative chemotherapy, as evidenced by a high degree of tumor necrosis, have 5-year overall survival (OS) rates of 75% to 80%; those who respond poorly to preoperative chemotherapy have 5-year OS rates of 45% to 55% (Bielack et al., 2002). Those who present with metastatic disease have long-term OS rates in the range of 10% to 40% (Goorin et al., 2002). Background Histological response to preoperative chemotherapy is strongly associated with survival in pediatric osteosarcoma. At the time of local control, this response is estimated by measuring the percentage of tumor necrosis in the resected specimen. The percentage of tumor necrosis correlates with chemosensitivity and clinical outcome (Eilber et al., 2001). The point at which degree of necrosis is determined to be significant has been somewhat controversial. Most groups now define a good histological response as having less than 10% viable tumor at the time of surgery. A poor response is defined as the presence of more than 10% viable tumor cells (Link et al., 2002; Marina et al., 2004). Results of the Pediatric Oncology Group (POG) protocol for localized osteosarcoma, termed POG 9351, or Children s Cancer Group (CCG) 7921, found that 45% of patients had favorable responses (>90% necrosis) following preoperative chemotherapy (Meyers et al., 2005). At our center, however, some clinicians questioned the tumor necrosis results in our patients. The POG 9351/CCG 7921 regimen A protocol is currently the protocol used at our center as the standard of care for patients with localized high-grade osteosarcoma in the absence of an open clinical trial. The primary objective of this study was to determine whether there had been an overall change in tumor necrosis over the past 10 years in patients treated for localized osteosarcoma of the extremity on the POG 9351/CCG 7921 protocol. Secondary objectives were (1) to qualitatively describe the proportion of patients with a good response to preoperative chemotherapy (>90% necrosis) to examine whether our institutional outcomes were similar to those reported in the literature and (2) to evaluate the relationship between tumor necrosis with clinical outcome. Patients and Methods A retrospective chart review was performed, after having obtained institutional research ethics board approval. Patients with localized osteosarcoma of the extremity were identified from 1993, the year in which the POG 9351/CCG 7921 protocol was opened, through 2003, the year this study closed. A list of patients was generated through the hospital s database of oncology diagnoses. All patients with localized, high-grade osteosarcoma of the extremity were identified, and those treated on or as per the POG 9351/CCG 7921 regimen A were included in the study. Preoperative chemotherapy included 2 full cycles of chemotherapy. Each cycle included 1 course of cisplatin and doxorubicin and 2 courses of high-dose methotrexate (Table 1). Patients with secondary osteosarcomas were excluded from the study because of their prior exposure to chemotherapy agents. 178 Journal of Pediatric Oncology Nursing 23(4); 2006
4 Tumor Necrosis in Pediatric Osteosarcoma Table 1. Chemotherapy Agents and Doses Used Before Local Control (2 Cycles) 12 Drug Dose Day Cisplatin 120 mg/m 2 1 Doxorubicin 25 mg/m (72-hour continuous infusion) Methotrexate 12 g/m 2 21 Methotrexate 12 g/m 2 28 Number of Patients Information regarding age, date of diagnosis, date of surgery, tumor location, and type of surgery was collected. Statistical Analysis For the primary objective, we examined whether there was an association between percentage tumor necrosis and year of diagnosis using Spearman s correlation coefficient. To examine whether the percentage of tumor necrosis was associated with patient outcomes including OS, the Cox proportional hazards model was used. 2 0 Figure 3. >90% 70-79% 50-59% 30-39% 10-19% Degree of Tumor Necrosis (%) Patients With Various Degrees of Histological Response Following Preoperative Chemotherapy Results From January 1993 to November 2003, 24 patients were treated according to the POG 9351/CCG/7921 regimen A protocol at our institution. Two had secondary osteosarcomas and 1 had a complete resection before receiving chemotherapy and were excluded, leaving 21 patients who were included in our study. The median age at diagnosis was 13.1 years (range, years). The median degree of tumor necrosis was 90% (range, 10%-99%). The 3-year OS was 71% ± 11%. Fifty-two percent (11) of children showed a good histological response, defined as more than 90% necrosis (Figure 3). There was no relationship between necrosis and year of surgery (r = 0.06, P =.8) (Figure 4). There was no relationship between percentage necrosis and OS (hazard ratio 0.98, P =.2). There was almost no power to look at this though because there were only 5 deaths out of the 21 patients. Discussion We found that despite our clinical suspicion, there was no change in the percentage necrosis over the 10-year Figure 4. No Correlation Between Percentage Necrosis and Year of Treatment period of our study, and the proportion of patients at our institution with a good response to preoperative chemotherapy was similar to that reported in the literature. One limitation of our study is that we only included those patients receiving 1 particular chemotherapy regimen. Nonetheless, because it was patients following this regimen who contributed to the recent observations of inferior necrosis rates who prompted this review, examination of just those patients following the POG 9351/CCG 7921 regimen A protocol was justifiable. Journal of Pediatric Oncology Nursing 23(4);
5 Hendershot et al. The results of this review were reassuring in that they reinforced for us that tumor necrosis responses to preoperative chemotherapy at our institution are similar to rates reported by Meyers and colleagues (2005) for the entire study group. Our initial concern was raised because we had 3 consecutive patients in 8 months who experienced inferior necrosis rates in 2003, prompting this review (Figure 4). The phenomenon of regression to the mean is a possible explanation for our recent results with poor tumor necrosis at our institution. This statistical phenomenon can make normal variations in repetitive data look like an actual change or trend (Barnett, van der Pols, & Dobson, 2005). When extreme observations are observed, on average, the next observation will be closer to the mean value. Regression to the mean can make effects attributable to chance look like real change (Morton & Torgerson, 2003). This type of situation can have serious implications in health care. If action is taken based on 1 abnormal result and a treatment is prescribed, then the intervention may look as though it was successful because the successive measurement is closer to the mean. Regression to the mean, however, would predict that the repeated measurements without the intervention would likely have been closer to the mean regardless. We had hypothesized that delays in chemotherapy administration, medication administration methods, medication timing, and drug resistance as well as changing tumor biology could potentially account for changes in response to preoperative chemotherapy in patients with osteosarcoma at our institution. However, the results that we obtained were important to alleviate concerns that institutional practices were contributing to our patients having perceived worse outcomes than those reported in the literature. Conclusions There was no change in histological response to preoperative chemotherapy in patients with highgrade osteosarcoma of the extremity over the past 10 years treated at our institution on the POG 9351/CCG 7921 regimen A protocol. Our results were congruent with those reported in the literature. These results and this study do, however, highlight 2 very important points. The first is the importance of recognizing limitations and dangers of basing medical decisions and practice on anecdotal evidence and case reports. The second point stresses the value of rigorous analyses using retrospective reviews. Natural variation in data may appear significant when in fact successive measurements will likely show that they are closer to the mean. These findings highlight the importance of performing rigorous data analyses using retrospective reviews before implementing treatment changes. Acknowledgments We thank Carol Winter, RN, data manager at the Hospital for Sick Children, for her assistance in obtaining a list of patients from the hematology/oncology database. References Bacci, G., Ferrari, S., Longhi, A., Forni, C., Zavatta, M., Versare, M., et al. (2002). High-grade osteosarcoma of the extremity: Differences between localized and metastatic tumors at presentation. Journal of Pediatric Hematology Oncology, 24, Barnett, A. G., van der Pols, J., & Dobson, A. J. (2005). Regression to the mean: What it is and how to deal with it. International Journal of Epidemiology, 34, Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Fledge, S., Helmke, K., et al. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 20, Davis, A. M., Bell, R. S., & Goodwin, P. J. (1994). Prognostic factors in osteosarcoma: A critical review. Journal of Clinical Oncology, 12, Eilber, F. C., Rosen, G., Eckardt, J., Forscher, C., Nelson, S. D., Selch, M., et al. (2001). Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. Journal of Clinical Oncology, 19, Goorin, A. M., Harris, M. B., Bernstein, M., Ferguson, W., Devidas, M., Siegal, G. P., et al. (2002). Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. Journal of Clinical Oncology, 20(2) Hartford, C. M., Wodowski, K. S., Rao, B. N., Khoury, J. D., Neel, M. D., & Daw, N. C. (2006). Osteosarcoma among children aged 5 years or younger: The St. Jude children s research hospital experience. Journal of Pediatric Hematology Oncology, 28, Jurgens, H., Winkler, K., & Gobel, U. (1997). Bone tumours. In C. R. Pinkerton & P. N. Plowman (Eds.), Paediatric oncology (2nd ed., pp ). London: Chapman & Hall. Kager, L., Zoubek, A., Potschger, U., Kastner, U., Flege, S., Kempf- Bielack, B., et al. (2003). Primary metastatic osteosarcoma: 180 Journal of Pediatric Oncology Nursing 23(4); 2006
6 Tumor Necrosis in Pediatric Osteosarcoma Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 21, Link, M. P., Gebhardt, M. C., & Meyers, P. A. (2002). Osteosarcoma. In P. A. Pizzo & D. G. Poplack (Eds.), Principles and practice of pediatric oncology (4th ed., pp ). Philadelphia: Lippincott Williams & Wilkins. Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 9, Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E., Betcher, D., Bernstein, M. L., et al. (2005). Osteosarcoma: A randomized, prospective trial of the addition of the ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology, 23, Morton, V., & Torgerson, D. J. (2003). Effect of regression to the mean on decision making in health care. British Medical Journal, 326, Pinkerton, C. R. (1999). Osteogenic sarcoma. In C. R. Pinkerton, A. J. Michalski, & P. A. Veys (Eds.), Clinical challenges in paediatric oncology (pp ). Oxford, UK: ISIS Medical Medial. Ragland, B. D., Bell, W. C., Lopez, R. R., & Siegal, G. P. (2002). Cytogenetic and molecular biology of osteosarcoma. Laboratory Investigation, 82, Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979). Primary osteogenic sarcoma. The rational for pre-operative chemotherapy and delayed surgery. Cancer, 43, Zalupski, M. M., Rankin, C., Ryan, J. R., Lucas, D. R., Muler, J., Lanier, K. S., et al. (2004). Adjuvant therapy of osteosarcoma A phase II trial. Cancer, 100, Continuing Education Credit The Journal of Pediatric Oncology Nursing is pleased to offer the opportunity to earn pediatric hematology/oncology nursing continuing education credit for this article online. Go to and select Continuing Education. There you can read the article again or go directly to the posttest assessment. The cost is $15 for each article. You will be asked for a credit card or online payment service number. The posttest consists of 10 questions based on the article, plus several assessment questions (e.g., how long did it take you to read the article and complete the posttest?). A passing score of 80% (8 of 10 questions correct) on the posttest and completion of the assessment questions yields one hour of continuing education in pediatric hematology/oncology nursing for each article. Journal of Pediatric Oncology Nursing 23(4);
Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationClinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation
Cancer Res Treat. 2008;40(4):172-177 Clinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation Ji Won Lee, M.D.
More informationMalignant bone tumors. Incidence Myeloma 45% Osteosarcoma 24% Chondrosarcoma 12% Lyphoma 8% Ewing s Sarcoma 7%
Malignant bone tumors Incidence Myeloma 45% Osteosarcoma 24% Chondrosarcoma 12% Lyphoma 8% Ewing s Sarcoma 7% Commonest primary bone sarcoma is osteosarcoma X ray Questions to ask 1. Solitary or Multiple
More informationSurvival of Pediatric Patients After Relapsed Osteosarcoma: The St. Jude Children s Research Hospital Experience
Survival of Pediatric Patients After Relapsed Osteosarcoma: The St. Jude Children s Research Hospital Experience Sarah E. S. Leary, MD 1,2 ; Amy W. Wozniak, MS 3 ; Catherine A. Billups, MS 2 ; Jianrong
More informationPerioperative chemotherapy in the treatment of osteosarcoma: a 26 year single institution review
DOI 10.1186/s13569-015-0032-0 CLINICAL SARCOMA RESEARCH RESEARCH Open Access Perioperative chemotherapy in the treatment of osteosarcoma: a 26 year single institution review G M O Kane 1*, K A Cadoo 2,
More informationA Guide to Ewing Sarcoma
A Guide to Ewing Sarcoma Written By Physicians For Physicians WHAT IS EWING SARCOMA (ES) ES is a malignant bone tumor that can evolve from any bone in the body (and occasionally soft tissue) and mostly
More informationResponse of Osteosarcoma to Chemotherapy in Scotland. Ewan Semple, 5 th Year Medical Student, University of Aberdeen
Response of Osteosarcoma to Chemotherapy in Scotland Ewan Semple, 5 th Year Medical Student, University of Aberdeen 1 Summary Introduction Osteosarcomas are the most common primary bone tumour and affect
More informationPediatric Blood & Cancer. Good Prognosis of Localized Osteosarcoma in Young Patients Treated with Limb-Salvage Surgery and Chemotherapy
Pediatric Blood & Cancer Good Prognosis of Localized Osteosarcoma in Young Patients Treated with Limb-Salvage Surgery and Chemotherapy Journal: Pediatric Blood & Cancer Manuscript ID: PBC-10-0637.R3 Wiley
More informationHistorically, patients with osteosarcoma (OS) had a dismal prognosis, Adjuvant Therapy of Osteosarcoma A Phase II Trial
818 Adjuvant Therapy of Osteosarcoma A Phase II Trial Southwest Oncology Group Study 9139 Mark M. Zalupski, M.D. 1 Cathryn Rankin, M.S. 2 James R. Ryan, M.D. 3 David R. Lucas, M.D. 4 Jeffrey Muler, M.D.
More informationPrimary bone tumors > metastases from other sites Primary bone tumors widely range -from benign to malignant. Classified according to the normal cell
Primary bone tumors > metastases from other sites Primary bone tumors widely range -from benign to malignant. Classified according to the normal cell counterpart and line of differentiation. Among the
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationSoft Tissue Sarcoma. Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee
Soft Tissue Sarcoma Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee Soft Tissue Sarcoma Collective term for an unusual and diverse
More informationCarboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.2.1101 Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma in Thailand RESEARCH ARTICLE Carboplatin and Doxorubicin in Treatment of Pediatric
More informationTherapy Related Changes in Osteosarcoma and Ewing Sarcoma of Bone
The Open Pathology Journal, 2009, 3, 99-105 99 Open Access Therapy Related Changes in Osteosarcoma and Ewing Sarcoma of Bone Hye Sook Min 1, Hyun Guy Kang 2 and Jae Y. Ro *,3 1 Department of Pathology
More informationFirst results of the EURAMOS-1 Good Response randomization
plus maintenance pegylated interferon -2b (ifn) versus alone in patients with resectable high-grade osteosarcoma and good histological response to preoperative : First results of the EURAMOS-1 Good Response
More informationLong-Term Survivals of Stage IIB Osteosarcoma: A 20-Year Experience in a Single Institution
Original Article Clinics in Orthopedic Surgery 2011;3:48-54 doi:10.4055/cios.2011.3.1.48 Long-Term Survivals of Stage IIB Osteosarcoma: A 20-Year Experience in a Single Institution Yool Cho, MD, Gu-Hee
More informationWe have studied 560 patients with osteosarcoma of a
Osteosarcoma of the limb AMPUTATION OR LIMB SALVAGE IN PATIENTS TREATED BY NEOADJUVANT CHEMOTHERAPY G. Bacci, S. Ferrari, S. Lari, M. Mercuri, D. Donati, A. Longhi, C. Forni, F. Bertoni, M. Versari, E.
More informationFollow-up practices for high-grade extremity Osteosarcoma
Rothermundt et al. BMC Cancer (2016) 16:301 DOI 10.1186/s12885-016-2333-y RESEARCH ARTICLE Open Access Follow-up practices for high-grade extremity Osteosarcoma Christian Rothermundt 1*, Beatrice M. Seddon
More informationClinical features in osteosarcoma and prognostic implications
0021-7557/04/80-01/65 Jornal de Pediatria Copyright 2004 by Sociedade Brasileira de Pediatria ORIGINAL ARTICLE Clinical features in osteosarcoma and prognostic implications Ângela Rech 1, Cláudio G. Castro
More informationRadiology - Pathological Correlation of Osteosarcoma in a Tertiary Care Hospital - A Retrospective Study
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/235 Radiology - Pathological Correlation of Osteosarcoma in a Tertiary Care Hospital - A Retrospective Study P Kannan
More informationLimb Salvage Surgery for Musculoskeletal Oncology
Editorial Limb Salvage Surgery for Musculoskeletal Oncology Wan Faisham Nu man Bin Wan Ismail Submitted: 2 May 2015 Accepted: 18 June 2015 Orthopaedic Oncology Unit, Orthopaedic Department, School of Medical
More informationClinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy
Curr Oncol, Vol. 21, pp. e678-684; doi: http://dx.doi.org/10.3747/co.21.1973 XU et al. ORIGINAL ARTICLE Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy
More information2. Select the appropriate diagnostic work-up for patients with newly diagnosed osteosarcoma.
The Oncologist Pediatric Oncology Biology and Therapeutic Advances for Pediatric Osteosarcoma NEYSSA MARINA, a MARK GEBHARDT, b LISA TEOT, c RICHARD GORLICK d a Department of Pediatrics, Division of Hematology-Oncology,
More informationThe Radiology Assistant : Bone tumor - ill defined osteolytic tumors and tumor-like lesions
Bone tumor - ill defined osteolytic tumors and tumor-like lesions Henk Jan van der Woude and Robin Smithuis Radiology department of the Onze Lieve Vrouwe Gasthuis, Amsterdam and the Rijnland hospital,
More informationThe other bone sarcomas
ONCOLOGY The other bone sarcomas PROGNOSTIC FACTORS AND OUTCOMES OF SPINDLE CELL SARCOMAS OF BONE E. E. Pakos, R. J. Grimer, D. Peake, D. Spooner, S. R. Carter, R. M. Tillman, S. Abudu, L. Jeys From Royal
More informationResearch Article Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma
Sarcoma, Article ID 902620, 8 pages http://dx.doi.org/10.1155/2014/902620 Research Article Clinical Features and Outcomes Differ between and Osteosarcoma Sheila Thampi, 1 Katherine K. Matthay, 1 W. John
More informationOriginal article. F. Gherlinzoni, P. Picci, G. Bacci & D. Campanacci
Annals of Oncology 3 (Suppl. 2): S23-S27, 1992. 1992 Kluwer Academic Publishers. Printed in the Netherlands. Original article Limb sparing versus amputation in osteosarcoma Correlation between local control,
More informationORIGINAL ARTICLE. Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors
Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors Predictors of Survival? Robert C. G. Martin II, MD; Murray F. Brennan, MD ORIGINAL ARTICLE Background: Ewing sarcoma (ES) is the second
More informationYu-Jing Huang, Ai-Na He, Yuan-Jue Sun, Zan Shen, Da-Liu Min, Yang Yao*
RESEARCH ARTICLE Continuous-infusion Ifosfamide and Doxorubicin Combination as Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study Yu-Jing Huang,
More informationJOURNAL OF CLINICAL ONCOLOGY DIAGNOSIS IN ONCOLOGY
VOLUME 30 NUMBER 33 NOVEMBER 20 2012 JOURNAL OF CLINICAL ONCOLOGY DIAGNOSIS IN ONCOLOGY Lymph Node Metastasis of Osteosarcoma Case Report A 19-year-old man presented with a 12-month history of a swollen
More informationUK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky
UK Musculoskeletal Oncology: Something for All Ages Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky Pediatric-Type Sarcomas of Bone and Soft Tissue The incidence of sarcoma continues
More informationBone Tumors Clues and Cues
William Herring, M.D. 2002 Bone Tumors Clues and Cues In Slide Show mode, advance the slides by pressing the spacebar All Photos Retain the Copyright of their Authors Clues by Appearance of Lesion Patterns
More informationOsteosarcomas. Osteosarcoma. Epidemiology 4/12/2018. David R. Lucas, MD
Osteosarcomas David R. Lucas, MD Osteosarcoma Most common primary malignant bone tumor Neoplastic cells produce osteoid Before chemotherapy almost always fatal Now long term survival 60 65% Urgent need
More informationOsteosarcoma with atypical location in an elderly female patient
45 Autopsy and Case Reports 2011; 1(4): 45-49 Article / Clinical Case Report Artigo / Relato de Caso Clínico Osteosarcoma with atypical location in an elderly female patient Daniel Cury Ogata a, Rafael
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 17 November 2010 MEPACT 4 mg, powder for suspension for infusion B/1 (CIP code: 398331 6) Applicant : IDM PHARMA S.A.S
More informationLAC + USC.
Jeff McDavit,, M.D. LAC + USC mcdavit@usc.edu Clinical History 55 year old male with large, deep, non- tender left thigh mass. Seen at LAC+USC Med Ctr FNA clinic No h/o trauma or radiation Vimentin
More informationWe studied the CT and MR scans, and the
Tumour volume as a predictor of necrosis after chemotherapy in Ewing s sarcoma A. Abudu, A. M. Davies, P. B. Pynsent, D. C. Mangham, R. M. Tillman, S. R. Carter, R. J. Grimer From the Royal Orthopaedic
More informationCerebral metastases from malignant brous histiocytoma of bone
Sarcoma (2000) 4, 125± 128 CASE REPORT Cerebral metastases from malignant brous histiocytoma of bone SUSANNE J. ROGERS & JEREMY S. WHELAN London Bone and Soft Tissue Tumour Service, Middlesex Hospital,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationOpen Access. Michael J. Cascio 1, Richard J. O Donnell 2, Robert E. Goldsby 3 and Andrew E. Horvai *,1
Send Orders for Reprints to reprints@benthamscience.net The Open Pathology Journal, 2013, 7, 7-15 7 Open Access Are Areas of Isolated Atypical Cells or Residual Tumor Cartilage Prognostically Significant
More informationCase 8 Soft tissue swelling
Case 8 Soft tissue swelling 26-year-old female presented with a swelling on the back of the left knee joint since the last 6 months and chronic pain in the calf and foot since the last 2 months. Pain in
More informationFrontline Treatment of Localized Osteosarcoma Without Methotrexate
Frontline Treatment of Localized Osteosarcoma Without Methotrexate Results of the St. Jude Children s Research Hospital OS99 Trial Najat C. Daw, MD 1,2 ; Michael D. Neel, MD 3 ; Bhaskar N. Rao, MD 3,4
More informationMalignant Bone Tumours. PathoBasic, Daniel Baumhoer
Malignant Bone Tumours PathoBasic, 20.03.18 Daniel Baumhoer FNCLCC Grading The differentiation score is defined as the extent to which a tumor resembles adult mesenchymal tissue (score 1), the extent to
More informationRetrospective analysis of the eff
JBUON 2018; 23(6): 1809-1815 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Retrospective analysis of the effect of treatment of osteosarcoma
More informationMARK D. MURPHEY MD, FACR. Physician-in-Chief, AIRP. Chief, Musculoskeletal Imaging
ALPHABET SOUP AND CYSTIC LESIONS OF THE BONE MARK D. MURPHEY MD, FACR Physician-in-Chief, AIRP Chief, Musculoskeletal Imaging ALPHABET SOUP AND CYSTIC LESIONS OF THE BONE Giant cell tumor (GCT) Unicameral
More informationHigh grade focal areas in low grade central osteosarcoma: high grade or still low grade osteosarcoma?
DOI 10.1186/s13569-015-0038-7 CLINICAL SARCOMA RESEARCH RESEARCH High grade focal areas in low grade central osteosarcoma: high grade or still low grade osteosarcoma? Alberto Righi 1*, Anna Paioli 2, Angelo
More informationOsteosarcoma (Canine)
Osteosarcoma (Canine) Answering Your Questions About Osteosarcoma In Dogs What Is Osteosarcoma? Usual Sites for Osteosarcoma Development Osteosarcoma is by far the most common bone tumor of the dog, usually
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationMRI XR, CT, NM. Principal Modality (2): Case Report # 2. Date accepted: 15 March 2013
Radiological Category: Musculoskeletal Principal Modality (1): Principal Modality (2): MRI XR, CT, NM Case Report # 2 Submitted by: Hannah Safia Elamir, D.O. Faculty reviewer: Naga R. Chinapuvvula, M.D.
More informationChemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience
Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience Smeland, S.; Wiebe, Thomas; Böhling, T.; Brosjö, O.; Jonsson, Kjell; Alvegård, Thor Published in: Acta Orthopaedica Scandinavica
More informationGIANT CELL-RICH OSTEOSARCOMA: A CASE REPORT
Nagoya J. Med. Sci. 59. 151-157, 1996 CASE REPORTS GIANT CELL-RICH OSTEOSARCOMA: A CASE REPORT KEIJI SATO!, SHIGEKI YAMAMURA!, HISASHI IWATA!, HIDESHI SUGIURA 2, NOBUO NAKASHIMA 3 and TETSURO NAGASAKA
More informationEffectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review protocol
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review protocol Rincy Jimmy, BSc (Hons), MSc (Hons) 1 Sarahlouise White, BSc (Hons), MClinSci,
More informationCOPYRIGHT 2004 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED
84 COPYRIGHT 2004 BY THE JOURNAL BONE AND JOINT SURGERY, INCORPORATED Radiographic Evaluation of Pathological Bone Lesions: Current Spectrum of Disease and Approach to Diagnosis BY BENJAMIN G. DOMB, MD,
More informationOriginal article. Introduction
Original article Annals of Oncology 14: 1126 1134, 2003 DOI: 10.1093/annonc/mdg286 Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the
More informationJ Clin Oncol 30: by American Society of Clinical Oncology INTRODUCTION
VOLUME 30 NUMBER 17 JUNE 10 2012 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic
More informationThe optimal treatment of osteosarcoma is comprised of multiagent. Outcome after Local Recurrence of Osteosarcoma
1928 Outcome after Local Recurrence of Osteosarcoma The St. Jude Children s Research Hospital Experience (1970 2000) Carlos Rodriguez-Galindo, M.D. 1,2 Nirali Shah, M.D. 1 M. Beth McCarville, M.D. 3 Catherine
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Musculoskeletal tumours Faculty of Clinical Radiology www.rcr.ac.uk Contents Primary bone tumours 3 Clinical
More informationBone Tumours - a synopsis. Dr Zena Slim SpR in Histopathology QAH 2009
Bone Tumours - a synopsis Dr Zena Slim SpR in Histopathology QAH 2009 Aims General approach to diagnosis Common entities.and not so common ones. Mini quiz Challenge of bone tumour diagnosis Bone tumours
More informationMusculoskeletal Sarcomas
Musculoskeletal Sarcomas Robert C. Orth, M.D., Ph.D. Edward B. Singleton Department of Pediatric Radiology Texas Children s Hospital Page 0 xxx00.#####.ppt 9/23/2012 9:01:18 AM No disclosures Page 1 xxx00.#####.ppt
More informationIntra-arterial Cis-platinum in Osteosarcoma
Haematology and Blood Transfusion Vol. 31 Modern Trends in Human Leukemia VII Edited by Neth, Gallo, Greaves, and Kabisch Springer-Verlag Berlin Heidelberg 1987 Intra-arterial Cis-platinum in Osteosarcoma
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationJAMES EWING, Endothelial origin. 14 yr Girl
JAMES EWING, 1921 Endothelial origin 14 yr Girl SPECTRUM OF ESFT NEURAL DIFFERENTIATION Least Well EWING S SARCOMA ATYPICAL EWING S SARCOMA PNET Peripheral Neuroepithelioma ASKIN TUMOR (thoraco-pulmonary)
More informationResearch Article Osteosarcoma in Pediatric Patients and Young Adults: A Single Institution Retrospective Review of Presentation, Therapy, and Outcome
Sarcoma, Article ID 402509, pages http://dx.doi.org/.1155/2014/402509 Research Article Osteosarcoma in Pediatric Patients and Young Adults: A Single Institution Retrospective Review of Presentation, Therapy,
More informationRole of Surgical Margin on Local Recurrence in High Risk Extremity Osteosarcoma: A Case-Controlled Study
Original Article Clinics in Orthopedic Surgery 2013;5:216-224 http://dx.doi.org/10.4055/cios.2013.5.3.216 Role of Surgical Margin on Local Recurrence in High Risk Extremity Osteosarcoma: A Case-Controlled
More informationOsteosarcoma in Patients Younger Than 12 Years Old Without Metastases Have Similar Prognosis as Adolescent and Young Adults
Pediatr Blood Cancer 2015;62:1209 1213 Osteosarcoma in Patients Younger Than 12 Years Old Without Metastases Have Similar Prognosis as Adolescent and Young Adults Sabrina Jeane Prates Eleutério, MD, 1
More informationWhat s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer
What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer ESMO conference 2012 Top Oncologists in world (~ 400) Lots of sarcoma basic science key messages: 40% of STS diagnoses
More informationHistory. 33 y/o F with hx of palpable anterior tibial mass x 2 years, only painful with palpation
History 33 y/o F with hx of palpable anterior tibial mass x 2 years, only painful with palpation Imaging Photo Album Patient also had a smaller lesion 1 cm proximal to this lesion, not seen radiographically.
More informationUniversity Journal of Surgery and Surgical Specialities
University Journal of Surgery and Surgical Specialities Volume 1 Issue 1 2015 EXTRA SKELETAL MESENCHYMAL CHONDROSARCOMA :A CASE REPORT Rajaraman R Subbiah S Navin Naushad Kilpaulk Medical College Abstract:
More informationOsteosarcoma is a malignant mesenchymal neoplasm
Original Articles Histopathologic Features of Prognostic Significance in High-Grade Osteosarcoma Michael Herman Chui, MD; Rita A. Kandel, MD; Marcus Wong, BSc; Anthony M. Griffin, MSc; Robert S. Bell,
More informationEvaluation of surgical treatment results in parosteal osteosarcoma
Original Research Medical Journal of the Islamic Republic of Iran.Vol. 24, No. 1, May, 2010. pp. 11-16. Downloaded from mjiri.iums.ac.ir at 1:31 IRDT on Wednesday September 19th 2018 Evaluation of surgical
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationDiagnosis and staging of osteosarcoma
Original Article Diagnosis and staging of osteosarcoma Mayank Shukla 1*, Amrta Tiwari 2, Ankita Kakkar 3, Anupama Srivastava 4 { 1 Associate Professor, Department of Orthopaedics} { 2 Assistant Professor,
More informationAlthough second only to myeloma as the most
A Case Report & Literature Review Talar Osteosarcoma in an Elderly Woman Bradley S. Ellison, MD, Michael Potter, MD, Carl Morrison, MD, DVM, and Joel Mayerson, MD Although second only to myeloma as the
More informationA preliminary investigation of Beta-hCG expression in patients with osteosarcoma
ONCOLOGY A preliminary investigation of Beta-hCG expression in patients with osteosarcoma K. Z. Masrouha, R. Khattab, A. Tawil, A. Abdallah, S. Saghieh, R. Haidar, M. Abboud, N. J. Khoury From American
More informationVarious subtypes of osteosarcoma have been described,
Resident Short Review N Osteosarcoma is one of the most common primary malignant bone tumors in children and adolescents. Telangiectatic osteosarcoma is an unusual variant of osteosarcoma, forming 3% to
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bone and Soft Tissue 1/10/113. NAACCR Webinar Series
Collecting Cancer Data Bone & Soft Tissue NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
More informationAPMA 2018 Radiology Track Bone Tumors When to say Gulp!
APMA 2018 Radiology Track Bone Tumors When to say Gulp! DANIEL P. EVANS, DPM, FACFAOM Professor, Department of Podiatric Medicine and Radiology Dr. Wm. Scholl College of Podiatric Medicine Conflict of
More informationResults of thoracotomy in osteogenic sarcoma
Thorax 1991;46:727-731 Bone Tumour Treatment Service, Royal Orthopaedic Hospital, Birmingham B31 2AP S R Carter R J Grimer R S Sneath Thoracic Surgery Unit, East Birmingham Hospital, Birmingham B9 SST
More informationGrading of Bone Tumors
Grading of Bone Tumors Joon Hyuk Choi, M.D. Department of Pathology College of Medicine, Yeungnam University Introduction to grading system of bone tumor used at Mayo Clinic WHO Histologic Classification
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationRecently Intensified Chemotherapy for High-grade Osteosarcoma May Affect Fertility in Long-term Male Survivors
Recently Intensified Chemotherapy for High-grade Osteosarcoma May Affect Fertility in Long-term Male Survivors TSUKASA YONEMOTO, TAKESHI ISHII, YOSHIO TAKEUCHI, YOKO HAGIWARA, SHINTARO IWATA and SHIN-ICHIRO
More informationExtraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy
HAND (2015) 10:602 606 DOI 10.1007/s11552-015-9760-0 REVIEW Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy Dana L. Casey 1 & Matt van de Rijn 2 & Geoffrey
More informationDisclosures. Giant Cell Rich Tumors of Bone. Outline. The osteoclast. Giant cell rich tumors 5/21/11
Disclosures Giant Cell Rich Tumors of Bone Andrew Horvai, MD, PhD Associate Clinical Professor, Pathology This lecture discusses "off label" uses of a number of pharmaceutical agents. The speaker is describing
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 11/17/2012 Radiology Quiz of the Week # 99 Page 1 CLINICAL PRESENTATION AND RADIOLOGY
More informationOsteosarcoma: correlation between radiological and histological changes after intra-arterial chemotherapy
Osteosarcoma: correlation between radiological and histological changes after intra-arterial chemotherapy J.I. Bilbao 1, S. Martín Algarra 2, J. Martínez de Negri 3, F. Lecumberri 1, J. Longo 1, L. Sierrasesúmaga
More informationsarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.
1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,
More informationManagement of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience
Acta Oncologica, 2006; 45: 38 /46 ORIGINAL ARTICLE Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience LIV HEGE AKSNES 1, KIRSTEN SUNDBY HALL 1, GUNNAR FOLLERAAS
More informationAssociated Terms: Osteosarcoma, Bone Cancer, Limb Salvage, Appendicular Osteosarcoma, Pathologic Fracture, Chondrosarcoma
1 of 9 9/29/2014 8:25 PM Associated Terms: Osteosarcoma, Bone Cancer, Limb Salvage, Appendicular Osteosarcoma, Pathologic Fracture, Chondrosarcoma The term "ACVS Diplomate" refers to a veterinarian who
More informationSURGICAL MANAGEMENT OF OSTEOGENIC SARCOMA OF THE LOWER LIMB JOSEPH M. LANE, M.D., GERALD ROSEN, M.D.,
395 SURGICAL MANAGEMENT OF OSTEOGENIC SARCOMA OF THE LOWER LIMB JOSEPH M. LANE, M.D., GERALD ROSEN, M.D., PATRICK BOLAND, M.D., JAMES OTIS, PH.D., AND KAMEL ABOU ZAHR, M.D. Memorial Sloan-Kettering Cancer
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress OSTEOSARCOMA IN DOGS CAROLYN J. HENRY, DVM, MS, DACVIM (ONCOLOGY) University of Missouri-Columbia; Columbia,
More informationPrimary osteosarcoma of the spine
Acta Orthop. Belg., 2013, 79, 457-462 ORIGINAL STUDY Primary osteosarcoma of the spine A review of 10 cases Jason B.T. Lim, Himanshu Sharma, Elaine MacDuff, Anthony T. Reece From the Western Infirmary,
More informationO steosarcoma is the most common primary malignant
381 ORIGINAL ARTICLE The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter I Sulzbacher, P Birner, K Trieb, E Pichlbauer, S Lang... See end of article
More informationClinical Study Primary Malignant Tumours of Bone Following Previous Malignancy
Sarcoma Volume 2008, Article ID 418697, 4 pages doi:10.1155/2008/418697 Clinical Study Primary Malignant Tumours of Bone Following Previous Malignancy J. T. Patton, S. M. M. Sommerville, and R. J. Grimer
More informationOriginal Article A survival analysis and treatment outcomes of 131 cases of osteosarcoma treated with high-dose methotrexate multidrug chemotherapy 1
Int J Clin Exp Med 2016;9(5):8465-8473 www.ijcem.com /ISSN:1940-5901/IJCEM0020084 Original Article A survival analysis and treatment outcomes of 131 cases of osteosarcoma treated with high-dose methotrexate
More informationSurgical Approaches to Pulmonary Metastases
Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926
More informationMethotrexate Pharmacokinetics and Survival in Osteosarcomat
Methotrexate Pharmacokinetics and Survival in Osteosarcomat Irene Aquerreta, PharmD, PhD, 1 * Azucena Aldaz, PharmD, PhD, 1 Joaquín Giráldez, PharmD, PhD, 1 and Luis Sierrasesúmaga, MD, PhD 2 1 Department
More informationSynovial Sarcoma. Dr. Michelle Ghert Dr. Rajiv Gandhi
Synovial Sarcoma Dr. Michelle Ghert Dr. Rajiv Gandhi Synovial Sarcoma Young adult population (15-40yrs) 5-10% of all soft tissue sarcomas mainly found in the extremities 5 year survival only 60% at presentation;
More information